• Organizations: Neurotech Pharmaceuticals
Clinicians perform first FDA-approved ENCELTO treatment for MacTel
Products

Clinicians perform first FDA-approved ENCELTO treatment for MacTel

As the first-ever FDA-approved MacTel therapy, ENCELTO (revakinagene taroretcel-lwey) is a single-dose ocular implant administered via an outpatient vitreoretinal surgery.
BVI Medical and Neurotech name new CCOs
Business

BVI Medical and Neurotech name new CCOs

With over 20 years of executive leadership experience each, Andrew Chang and Beth Marsh will lead commercialization efforts for their respective companies’ upcoming product launches.
FDA approves Neurotech's ENCELTO cell therapy for MacTel
Products

FDA approves Neurotech's ENCELTO cell therapy for MacTel

Approval of revakinagene taroretcel-lwey is the first-ever for the treatment of this rare, neurodegenerative retinal disease. 
FDA extends Neurotech's BLA PDUFA date for MacTel therapy
Pipeline

FDA extends Neurotech's BLA PDUFA date for MacTel therapy

Review period of NT-501, an encapsulated cell therapy, now has a target date of March 2025.
KOLs eye the future of genetic engineering and cell transplantation
Events

KOLs eye the future of genetic engineering and cell transplantation

Industry leaders from four leading ophthalmic companies debut the latest clinical developments in cell-based therapeutics.
Neurotech Pharma earns BLA priority review for MacTel cell therapy
Pipeline

Neurotech Pharma earns BLA priority review for MacTel cell therapy

Investigational ocular implant is designed to slow progression of gradual central vision deterioration in rare neurodegenerative retinal disease.